Eton Pharmaceuticals (ETON) Fundamental Analysis: Revenue, Earnings & Valuation

0.75 / 10

Underperform

Fundamental assessment rates ETON at 0.8/10, indicating underperformance. Inventory and receivables turnover appear decent, but income‑tax ratio is negative and fixed‑asset turnover is low. Debt‑to‑equity (1.19) and negative PE (‑90.74) further stress the shaky financial health.

Analysis Checks(5/10)

Revenue-MV

Value-1.39

Score1/3

Weight47.78%

1M Return5.06%

Total operating revenue (YoY growth rate %)

Value104.94

Score2/3

Weight4.79%

1M Return0.58%

Inventory turnover ratio

Value2.43

Score2/3

Weight-5.68%

1M Return-0.66%

Accounts receivable turnover ratio

Value9.34

Score2/3

Weight-5.07%

1M Return-0.65%

PB-ROE

Value4.51

Score0/3

Weight37.05%

1M Return3.80%

Income tax / Total profit (%)

Value-0.94

Score1/3

Weight-4.64%

1M Return-0.59%

Fixed assets turnover ratio

Value189.23

Score1/3

Weight-9.50%

1M Return-1.28%

Interest coverage ratio (EBIT / Interest expense) (%)

Value34.91

Score2/3

Weight-5.72%

1M Return-0.73%

Cost of sales ratio (%)

Value46.54

Score2/3

Weight-5.61%

1M Return-0.74%

Asset-MV

Value-0.48

Score0/3

Weight46.60%

1M Return4.88%

Is ETON fundamentally strong?

ETON scores 0.75/10 on fundamentals and holds a Premium valuation at present. Backed by its -18.19% ROE, -5.75% net margin, -141.37 P/E ratio, 24.87 P/B ratio, and -13.33% earnings growth, these metrics solidify its Underperform investment rating.